Ramantamig  (Synonyms: JNJ-79635322; JNJ-5322)

Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma^[1].

immunoglobulin (H-gamma1-scFvkh_L-lambda2)_scFvkh-G1(h-CH2-CH3)

Human

CD3E & GPRC5D & TNFRSF17

Ramantamig (72 h) potently induces T-cell-mediated cytotoxicity and activation in BCMA-GPRC5D dual-positive human multiple myeloma cell lines (MM.1S, H929, JIM-3, OPM-2) with sub-nanomolar to low nanomolar EC₅₀ values, but has no effect on dual-negative myeloid cell lines^[1].
Ramantamig (72 h) induces potent T-cell-mediated cytotoxicity and activation in H929-WT, H929-BCMA-KO, and H929-GPRC5D-KO human multiple myeloma cell lines, with significantly higher potency against dual-target-expressing H929-WT cells^[1].
Ramantamig (48 h) potently induces T-cell-mediated cytotoxicity, T-cell activation, and proinflammatory cytokine production in H929 human multiple myeloma cells spiked into healthy human whole blood, with low nanomolar EC₅₀ values^[1].
Ramantamig (48 h) does not induce nonspecific T-cell activation or immune cell cytotoxicity in healthy human purified T cells or whole blood, except at very high concentrations (>10 nM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ramantamig (JNJ-79635322) (0.1-2.5 mg/kg; i.p.; twice weekly; 8 doses) induces dose-dependent tumor growth inhibition and complete regression in RPMI 8226 multiple myeloma xenografts, with the 2.5 mg/kg dose achieving 111.2% ΔTGI and 95.2% tumor regression by day 38, and 100% complete regression by day 60^[1].
Ramantamig (0.025-1 mg/kg; i.p.; twice weekly; 7 doses) induces dose-dependent tumor growth inhibition and complete regression in MM.1S multiple myeloma xenografts, with the 1 mg/kg dose achieving 109% ΔTGI and 100% tumor regression by day 34, and sustaining 100% complete regression by day 51^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

916  [NCBI] & 55507  [NCBI] & 608  [NCBI]

P07766 & Q9NZD1 & Q02223

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

153.279 kDa

2988886-91-3

Liquid

Colorless to light yellow

N/A

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  half-G1-lambda-scFvkh_scFvkh-h-CH2-CH3

• [1]. Pillarisetti K, et al. Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models. Blood. 2026;147(8):834-847.  [Content Brief]